Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS I: Elinzanetant for moderate to severe menopausal vasomotor symptoms
MOH_2021-11-27_010306Phase 3Completed
- Sponsor
- Bayer Consumer Health
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Elinzanetant 26 weeks with Placebo then elinzanetant (2 arms). Primary endpoint: Not reported. Started Nov 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on MOH_2021-11-27_010306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-27_010306.